Solvias achieves CHF 75.7 million in 2017 sales, driven by ongoing expansion in biopharmaceutical analysis
11th May 2018
In 2017, Swiss contract research and service provider Solvias continued on a solid growth path and significantly expanded its profitability for the fourth year running. Sales reached CHF 75.7 m, up 15.9% compared to the previous year. While the company performed well across the board, the strong contributions of Biopharmaceutical Analysis and Confarma deserve special mention. Sales growth for the Quality Control & Release unit as well as Excipients Testing also exceeded expectations. Solvias continued to expand internationally, generating 62% of its turnover outside Switzerland.
Solvias expanded its workforce to meet rising demand from customers, reaching a total of 461 employees in 2017 – an approximate 8% increase over the previous year. This reflects business trends toward increased outsourcing in the pharmaceutical industry, stricter quality controls for pharma, medtech and cosmetic products and a growing need for sophisticated analytical testing.
“Our growth trajectory continues to gain momentum,” said CEO Karen Huebscher. “We were able to fully harness favorable business tailwinds because of the trust customers have in our scientific competencies and our internal transformation efforts, including LEAN and professional project management.”
Due to the increasing demand for services, Solvias will continue to hire highly qualified people, particularly in Biopharmaceuticals. “We will continue to invest in innovation and look for partnerships to make the most of our in-house pipeline, as we are doing with our MAT kit,” underlined CEO Karen Huebscher. “Looking further into the future, we will position ourselves ahead of industry trends by continuously developing our skills, and through partnering and targeted acquisitions.”
For more information visit www.solvias.com/en/news-events/2018/04/Company-highlights-2017.php